The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects:

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Multivariate Cox proportional hazard analysis ratio of patient factors associated with treatment outcomes in HIV care, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Clinic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival curve of ART Treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by clinical characteristics <i>among participants in HIV care Facilities in</i> Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects: